ATLANTA, GA USA (UroToday) -
Pre-operative Aspirin users have lower Serum PSA level than Non-users
The Duke Prostate Cancer Center study (Abstract 2237) investigated whether long-term aspirin use lowers serum PSA levels. Aspirin has been shown to be associated with reduced risk for several cancers including colorectal cancer. The group sought to understand the pharmacologic influence of aspirin on PSA levels.
The study group involved 931 men with prostate cancer undergoing prostatectomy. These men had known aspirin maintenance use prior to surgery. The group used a Mann-Whitney test to determine associations of aspirin use with PSA levels. Results showed 325 men (35%) were prescribed aspirin prior to the surgery. Aspirin users tended to be older and Caucasian compared to non-users. After controlling various clinical and pathological confounders, aspirin use was significantly associated with lower PSA levels. The mean-adjusted PSA for aspirin users was 4.95 and for non-users 5.41. The 8.5% reduction in aspirin users needs to be verified in other radical prostatectomy cohorts and men without prostate cancer.
Presented by Cagri Senocak, Lionel Banez, Jean-Alfred Thomas, Roberto Muller, Leah Gerber, Cary Robertson, Thomas Polascik, Stephen Freedland, Philip Walther, and Judd Moul at the American Urological Association (AUA) Annual Meeting - May 19 - 23, 2012 - Georgia World Congress Center - Atlanta, GA USA
